# US 2016/0354464 A1 · Compositions and methods for modulating an immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354464 A1
- Document ID: US20160354464A1
- Status: Published application
- Kind: A1
- Application number: 15/178,028
- Filed: 2016-06-09
- Published: 2016-12-08
- Earliest claimed: 2008-05-08
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Charles G. Drake; Drew M. Pardoll; Jonathan D. Powell; Derese Getnet; Edward L. Hipkiss; Joseph F. Grosso
- Web page: https://patentgrep.com/patent/US20160354464A1

## CPC

- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- G01N 33/5011: {for testing antineoplastic activity}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2320/31: Combination therapy
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention generally features compositions and methods for modulating an immune response. In particular embodiments, such compositions and methods modulate regulatory T cell suppressive activity.

## Claims

### Claim at position 1

-2. (canceled)

### Claim 3

A method for increasing an effector T cell-mediated immune response, the method comprising contacting the cell with an agent that reduces Helios expression or biological activity, thereby increasing the immune response.

### Claim 4 (depends on 3)

The method of claim 3, wherein the method reduces Treg CD4+CD25+ T lymphocytes suppression of an effector T cell mediated immune response.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4, wherein the agent is a polypeptide, polynucleotide, or small compound.

### Claim 7 (depends on 6)

The method of claim 6, wherein the polynucleotide is an inhibitory nucleic acid molecule selected from the group consisting of siRNA, shRNA, or antisense oligonucleotide.

### Claim 8 (depends on 6)

The method of claim 6, wherein the agent disrupts Helios binding to a FoxP3 promoter.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent specifically binds a Helios polypeptide.

### Claim 10 (depends on 8)

The method of claim 8, wherein the agent binds the FoxP3 promoter at about nucleotides −1184 to −724 and/or −692 to −335 from transcriptional start site.

### Claim 11

A method for increasing an effector T cell-mediated immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces Helios expression or biological activity, thereby increasing the immune response.

### Claim 12 (depends on 11)

The method of claim 11, wherein the method reduces Treg suppressive activity.

### Claim 13 (depends on 11)

The method of claim 11, wherein the subject is identified as having a neoplasia or pathogen infection.

### Claim 14 (depends on 11)

The method of claim 11, wherein the subject is identified as having an autoimmune or inflammatory disease.

### Claim at position 14

-16. (canceled)

### Claim 17 (depends on 11)

The method of claim 11, wherein the agent reduces Helios expression or biological activity, thereby treating the neoplasia.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method reduces Treg suppression of an effector T cell mediated immune response.

### Claim 19 (depends on 17)

The method of claim 17, further comprising administering to the subject an immunogenic composition comprising a tumor antigen.

### Claim 20 (depends on 19)

The method of claim 19, wherein the method enhances an immune response against a tumor antigen.

### Claim 21 (depends on 11)

The method of claim 11, wherein the agent is a polypeptide, polynucleotide, or small compound.

### Claim 22 (depends on 21)

The method of claim 21, wherein the polynucleotide is an inhibitory nucleic acid molecule selected from the group consisting of siRNA, shRNA, or antisense oligonucleotide.

### Claim 23 (depends on 21)

The method of claim 21, wherein the polypeptide is an antibody that specifically binds a Helios polypeptide and disrupts a Helios/FoxP3 interaction.

### Claim 24 (depends on 21)

The method of claim 21, wherein the agent binds the FoxP3 promoter at about nucleotides −1184 to −724 and/or −692 to −335 from transcriptional start site and disrupts a Helios/FoxP3 interaction.

### Claim 25

A method for increasing the efficacy of an anti-neoplasia vaccine in a subject, the method comprising administering to the subject a vaccine comprising a tumor antigen and an agent that reduces the level or activity of a Helios polypeptide in a cell of the subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein the agent is a polypeptide, polynucleotide, or small compound.

### Claim 27 (depends on 25)

The method of claim 25, wherein the polynucleotide is a Helios inhibitory nucleic acid molecule selected from the group consisting of an siRNA, shRNA, or antisense oligonucleotide.

### Claim 28 (depends on 25)

The method of claim 25, wherein the Helios inhibitory nucleic acid molecule is an siRNA having the following nucleic acid sequence:
(SEQ ID NO: 1)
Sense:
CCUCACAAGUGCAACUACUtt
(SEQ ID NO: 2)
Antisense:
AGUAGUUGCACUUGUGAGGtt.

### Claim at position 27

-62. (canceled)
